Literature DB >> 22870094

Inhibition of pleural metastasis of collecting duct carcinoma of the kidney by modified cytokine-induced killer cells: A case report and review of the literature.

Jingyi Liu1, Jun Sui, Zhiwei Zhang, Xiubao Ren, Li Luan, Qisheng Yang, Songhai Gu, Rudolf Wank, Barbara Laumbacher, Xin Song.   

Abstract

Collecting duct carcinoma (CDC) or Bellini duct carcinoma of the kidney is a rare, but highly aggressive renal epithelial malignancy, with an extremely poor prognosis. Modified cytokine-induced killer (mCIK) cells were injected into the pleural cavity to treat pleural metastasis of CDC. The patient, a 33-year-old male, was admitted to hospital for further treatment for severe pleural metastasis of CDC. We cured the pleural metastasis through intrapleural infusion with mCIK cells. After receiving this innovative treatment, the patient exhibited a positive response: the cough, dyspnea, chest distress and thoracalgia were evidently relieved, while the pleural fluid became clear after exhibiting haematodes and its level decreased significantly. The patient achieved partial success. This novel immunotherapy method is a promising treatment for patients with refractory pleural metastasis.

Entities:  

Year:  2010        PMID: 22870094      PMCID: PMC3412461          DOI: 10.3892/ol.2010.168

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  15 in total

Review 1.  An unusual case of Bellini duct carcinoma.

Authors:  M I Anjum; P Y Ting; N Shrotri; B Randall; G R Mufti
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

2.  Is there a place for radical nephrectomy in the presence of metastatic collecting duct (Bellini) carcinoma?

Authors:  Arnaud Méjean; Morgan Rouprêt; Frédérique Larousserie; Vincent Hopirtean; Nicolas Thiounn; Bertrand Dufour
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

Review 3.  Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature.

Authors:  Matthew I Milowsky; Alyssa Rosmarin; Satish K Tickoo; Nicholas Papanicolaou; David M Nanus
Journal:  Cancer       Date:  2002-01-01       Impact factor: 6.860

4.  Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases.

Authors:  R Mancilla-Jimenez; R J Stanley; R A Blath
Journal:  Cancer       Date:  1976-12       Impact factor: 6.860

5.  Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients.

Authors:  M Schulze; A S Boehle; R Kurdow; P Dohrmann; D Henne-Bruns
Journal:  Ann Thorac Surg       Date:  2001-06       Impact factor: 4.330

6.  Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.

Authors:  Sandra Balkow; Karin Loser; Mathias Krummen; Tetsuya Higuchi; Tobias Rothoeft; Jenny Apelt; Andrea Tuettenberg; Carsten Weishaupt; Stefan Beissert; Stephan Grabbe
Journal:  Exp Dermatol       Date:  2008-10-22       Impact factor: 3.960

7.  Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.

Authors:  Jawaher Ansari; Arfeen Fatima; Shalini Chaudhri; Rupesh I Bhatt; Michael Wallace; Nicholas D James
Journal:  Onkologie       Date:  2009-01-19

8.  Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model.

Authors:  Naoko Yamada; Masaki Hata; Hideki Ohyama; Koji Yamanegi; Nahoko Kogoe; Keiji Nakasho; Hiroyuki Futani; Haruki Okamura; Nobuyuki Terada
Journal:  Tumour Biol       Date:  2009-09-09

9.  Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.

Authors:  Ming Shi; Bing Zhang; Zi-Rong Tang; Zhou-Yun Lei; Hui-Fen Wang; Yong-Yi Feng; Zhen-Ping Fan; Dong-Ping Xu; Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

10.  Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions.

Authors:  J W Millar; A M Hunter; N W Horne
Journal:  Thorax       Date:  1980-11       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.